Results 81 to 90 of about 1,317,143 (303)

Gastric Ewing Sarcoma identified on a Meckel's scan

open access: yesRadiology Case Reports, 2020
Ewing Sarcoma is a malignant small round blue cell tumor most commonly found in bones and soft tissues of the axial skeleton and extremities. The Ewing family of tumors, including peripheral neuroectodermal tumor, represent the second most common ...
Lavi Nissim, MD, Gerald Mandell, MD
doaj   +1 more source

Continuous Lyman-alpha generation by four-wave mixing in mercury for laser-cooling of antihydrogen

open access: yes, 2010
Cooling antihydrogen atoms is important for future experiments both to test the fundamental CPT symmetry by high-resolution laser spectroscopy and also to measure the gravitational acceleration of antimatter.
A. Beczkowiak   +9 more
core   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon   +13 more
wiley   +1 more source

The Higgs properties in the MSSM after the LHC Run-2

open access: yes, 2017
We scrutinize the parameter space of the SM-like Higgs boson in the minimal supersymmetric standard model (MSSM) under current experimental constraints.
Zhao, Jun
core   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

open access: yesMolecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla   +10 more
wiley   +1 more source

A note on generalized Genome Scan Meta-Analysis statistics

open access: yesBMC Bioinformatics, 2005
Background Wise et al. introduced a rank-based statistical technique for meta-analysis of genome scans, the Genome Scan Meta-Analysis (GSMA) method. Levinson et al.
Feng Anne C, Koziol James A
doaj   +1 more source

Optical Coherence Spectro-Tomography by all-Optical Depth-Wavelength analysis

open access: yes, 2006
Current spectroscopic optical coherence tomography (OCT) methods rely on a posteriori numerical calculation. We present an alternative for accessing optically the spectroscopic information in OCT, i.e.
Couderc, Vincent   +7 more
core   +2 more sources

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

open access: yesMolecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff   +11 more
wiley   +1 more source

Scan speed affects quantitative optical coherence tomography angiography vascular metrics

open access: yesScientific Reports
Optical coherence tomography angiography (OCTA) offers the possibility of obtaining objective quantification of retinal vasculature, with increasing utility as biomarkers for both systemic and ocular diseases.
Lourdes Vidal-Oliver   +4 more
doaj   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy